Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 232

1.

Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.

Grubbs CJ, Lubet RA, Atigadda VR, Christov K, Deshpande AM, Tirmal V, Xia G, Bland KI, Eto I, Brouillette WJ, Muccio DD.

Carcinogenesis. 2006 Jun;27(6):1232-9. Epub 2005 Dec 12.

2.

Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.

Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5488-96.

3.

Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.

Muccio DD, Brouillette WJ, Alam M, Vaezi MF, Sani BP, Venepally P, Reddy L, Li E, Norris AW, Simpson-Herren L, Hill DL.

J Med Chem. 1996 Sep 13;39(19):3625-35.

PMID:
8809153
4.

Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis.

Lubet RA, Christov K, Nunez NP, Hursting SD, Steele VE, Juliana MM, Eto I, Grubbs CJ.

Carcinogenesis. 2005 Feb;26(2):441-8. Epub 2004 Dec 9.

5.

Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3.

Cope MB, Steele VE, Eto I, Juliana MM, Hill DL, Grubbs CJ.

Oncol Rep. 2002 May-Jun;9(3):533-7.

PMID:
11956623
6.

Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.

Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH.

Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74.

7.
8.

Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention.

Cope MB, Steele VE, Lubet RA, Eto I, Juliana MM, Hill DL, Grubbs CJ.

Oncol Rep. 2004 Feb;11(2):465-9.

PMID:
14719085
9.

9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers.

Grubbs CJ, Hill DL, Bland KI, Beenken SW, Lin TH, Eto I, Atigadda VR, Vines KK, Brouillette WJ, Muccio DD.

Cancer Lett. 2003 Nov 10;201(1):17-24.

PMID:
14580682
10.

Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).

Vedell PT, Lu Y, Grubbs CJ, Yin Y, Jiang H, Bland KI, Muccio DD, Cvetkovic D, You M, Lubet R.

Mol Pharmacol. 2013 Mar;83(3):698-708. doi: 10.1124/mol.112.082404. Epub 2013 Jan 4.

11.

Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.

Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ.

Cancer Prev Res (Phila). 2009 Feb;2(2):161-7. doi: 10.1158/1940-6207.CAPR-08-0134.

13.
14.

Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.

Lubet RA, Clapper ML, McCormick DL, Pereira MA, Chang WC, Steele VE, Fischer SM, Juliana MM, Grubbs CJ.

Oncol Rep. 2012 May;27(5):1400-6. doi: 10.3892/or.2012.1673. Epub 2012 Feb 3.

PMID:
22307264
15.

Retinoid X receptor agonist elevation of serum triglycerides in rats by potentiation of retinoic acid receptor agonist induction or by action as single agents.

Standeven AM, Thacher SM, Yuan YD, Escobar M, Vuligonda V, Beard RL, Chandraratna RA.

Biochem Pharmacol. 2001 Dec 1;62(11):1501-9.

PMID:
11728386
16.

Retinoids in cancer chemoprevention.

Okuno M, Kojima S, Matsushima-Nishiwaki R, Tsurumi H, Muto Y, Friedman SL, Moriwaki H.

Curr Cancer Drug Targets. 2004 May;4(3):285-98. Review.

PMID:
15134535
17.

Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen.

Darro F, Cahen P, Vianna A, Decaestecker C, Nogaret JM, Leblond B, Chaboteaux C, Ramos C, Pétein M, Budel V, Schoofs A, Pourrias B, Kiss R.

Breast Cancer Res Treat. 1998 Sep;51(1):39-55.

PMID:
9877028
18.

Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention.

Rodríguez-Burford C, Lubet RA, Steele VE, Eto I, Bandy M, Juliana MM, Weiss HL, Grizzle WE, Kelloff GJ, Grubbs CJ.

Oncol Rep. 2001 Mar-Apr;8(2):373-9.

PMID:
11182059
19.

Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.

Lubet RA, Szabo E, Christov K, Bode AM, Ericson ME, Steele VE, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2008 Apr;7(4):972-9. doi: 10.1158/1535-7163.MCT-07-2141. Epub 2008 Mar 28.

20.

Retinoids as chemopreventive agents for breast cancer.

Moon RC, Mehta RG, Detrisac CJ.

Cancer Detect Prev. 1992;16(1):73-9. Review.

PMID:
1551141
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk